Research progress of cGAS-STING signaling pathway modulators in immunotherapy

LOU Fangning; ZHENG Mingyue; CHEN Kaixian; ZHANG Sulin

doi:10.11665/j.issn.1000-5048.2023112402

Journal of China Pharmaceutical University > 2024 > 55(1): 15-25. > DOI: 10.11665/j.issn.1000-5048.2023112402

LOU Fangning, ZHENG Mingyue, CHEN Kaixian, et al. Research progress of cGAS-STING signaling pathway modulators in immunotherapy[J]. J China Pharm Univ, 2024, 55(1): 15 − 25. DOI: 10.11665/j.issn.1000-5048.2023112402

Citation:

PDF (3415 KB)

Research progress of cGAS-STING signaling pathway modulators in immunotherapy

1.
School of Pharmacy, China Pharmaceutical University, Nanjing 211198
2.
Drug Discovery and Design Center, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China

Funds: This study was supported by the National Natural Science Foundation of China (No. T2225002, No.82273855); the National Key Research and Development Program of China (No. 2022YFC3400504); CAS Youth Innovation Promotion Association (No. 2023296)； and the Natural Science Foundation of Shanghai (No. 22ZR1474300)

More Information

Received Date: November 23, 2023
Available Online: March 05, 2024

Graphical Abstract

Abstract

Abstract

Upon monitoring cytoplasmic aberrant double-stranded DNA, cGAS-STING signaling pathway induces the expression of type I interferons and pro-inflammatory cytokines, which activates the host immune response and enhances anti-tumor immune response and resistance to pathogen infection. However, sustained activation of the cGAS-STING signaling pathway drives diseases such as autoimmune diseases, aging-associated inflammation, and neurodegenerative pathologies. Herein, we describe the mechanism by which cGAS-STING signaling pathway participates in regulating the development of various immune-related diseases, with a particular review of the research and development progress of STING agonists, cGAS inhibitors, and STING inhibitors, aiming to provide some theoretical reference for the future development of cGAS-STING modulators.
- cGAS-STING signaling pathway,
- STING agonist,
- cGAS inhibitor,
- STING inhibitor,
- immunotherapy

FullText(HTML)

References (59)

References

[1]	Mei JH, Hong Z, Wang C. Advances of drugs in targeting cGAS-STING signaling pathway[J]. J China Pharm Univ (中国药科大学学报), 2020, 51(3): 249-259. doi: 10.11665/j.issn.1000-5048.20200301
[2]	O’Neill LAJ. DNA makes RNA makes innate immunity[J]. Cell, 2009, 138(3): 428-430. doi: 10.1016/j.cell.2009.07.021
[3]	Zhong B, Yang Y, Li S, et al. The adaptor protein MITA links virus-sensing receptors to IRF3 transcription factor activation[J]. Immunity, 2008, 29(4): 538-550. doi: 10.1016/j.immuni.2008.09.003
[4]	Sun WX, Li Y, Chen L, et al. ERIS, an endoplasmic reticulum IFN stimulator, activates innate immune signaling through dimerization[J]. Proc Natl Acad Sci USA, 2009, 106(21): 8653-8658.
[5]	Jin L, Waterman PM, Jonscher KR, et al. MPYS, a novel membrane tetraspanner, is associated with major histocompatibility complex class Ⅱ and mediates transduction of apoptotic signals[J]. Mol Cell Biol, 2008, 28(16): 5014-5026. doi: 10.1128/MCB.00640-08
[6]	Cheng ZL, Dai T, He XL, et al. The interactions between cGAS-STING pathway and pathogens[J]. Signal Transduct Target Ther, 2020, 5(1): 91. doi: 10.1038/s41392-020-0198-7
[7]	Fuertes MB, Kacha AK, Kline J, et al. Host type I IFN signals are required for antitumor CD8⁺ T cell responses through CD8α⁺dendritic cells[J]. J Exp Med, 2011, 208(10): 2005-2016. doi: 10.1084/jem.20101159
[8]	Mullard A. Biotechs step on cGAS for autoimmune diseases[J]. Nat Rev Drug Discov, 2023, 22(12): 939-941. doi: 10.1038/d41573-023-00185-8
[9]	Corrales L, Glickman LH, McWhirter SM, et al. Direct activation of STING in the tumor microenvironment leads to potent and systemic tumor regression and immunity[J]. Cell Rep, 2015, 11(7): 1018-1030. doi: 10.1016/j.celrep.2015.04.031
[10]	Ramanjulu JM, Pesiridis GS, Yang JS, et al. Design of amidobenzimidazole STING receptor agonists with systemic activity[J]. Nature, 2018, 564(7736): 439-443. doi: 10.1038/s41586-018-0705-y
[11]	Woo SR, Fuertes MB, Corrales L, et al. STING-dependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumors[J]. Immunity, 2014, 41(5): 830-842. doi: 10.1016/j.immuni.2014.10.017
[12]	Lu L, Yang C, Zhou XY, et al. STING signaling promotes NK cell antitumor immunity and maintains a reservoir of TCF-1⁺ NK cells[J]. Cell Rep, 2023, 42(9): 113108. doi: 10.1016/j.celrep.2023.113108
[13]	Yan XW, Yao C, Fang C, et al. Rocaglamide promotes the infiltration and antitumor immunity of NK cells by activating cGAS-STING signaling in non-small cell lung cancer[J]. Int J Biol Sci, 2022, 18(2): 585-598. doi: 10.7150/ijbs.65019
[14]	Bakhoum SF, Ngo B, Laughney AM, et al. Chromosomal instability drives metastasis through a cytosolic DNA response[J]. Nature, 2018, 553(7689): 467-472. doi: 10.1038/nature25432
[15]	Li J, Hubisz MJ, Earlie EM, et al. Non-cell-autonomous cancer progression from chromosomal instability[J]. Nature, 2023, 620(7976): 1080-1088. doi: 10.1038/s41586-023-06464-z
[16]	Chang JH, Guo JT. Treatment of chronic hepatitis B with pattern recognition receptor agonists: current status and potential for a cure[J]. Antiviral Res, 2015, 121: 152-159. doi: 10.1016/j.antiviral.2015.07.006
[17]	Cerón S, North BJ, Taylor SA, et al. The STING agonist 5, 6-dimethylxanthenone-4-acetic acid (DMXAA) stimulates an antiviral state and protects mice against herpes simplex virus-induced neurological disease[J]. Virology, 2019, 529: 23-28. doi: 10.1016/j.virol.2019.01.006
[18]	Domizio JD, Gulen MF, Saidoune F, et al. The cGAS-STING pathway drives type Ⅰ IFN immunopathology in COVID-19[J]. Nature, 2022, 603(7899): 145-151. doi: 10.1038/s41586-022-04421-w
[19]	Xiao RX, Zhang A. Involvement of the STING signaling in COVID-19[J]. Front Immunol, 2022, 13: 1006395. doi: 10.3389/fimmu.2022.1006395
[20]	Liu NX, Pang XX, Zhang H, et al. The cGAS-STING pathway in bacterial infection and bacterial immunity[J]. Front Immunol, 2021, 12: 814709.
[21]	Zhu LF, Xu L, Wang CG, et al. T6SS translocates a micropeptide to suppress STING-mediated innate immunity by sequestering manganese[J]. Proc Natl Acad Sci U S A, 2021, 118(42): e2103526118. doi: 10.1073/pnas.2103526118
[22]	Chen T, Feng YT, Sun WW, et al. The nucleotide receptor STING translocates to the phagosomes to negatively regulate anti-fungal immunity[J]. Immunity, 2023, 56(8): 1727-1742. e6.
[23]	Hansen AL, Mukai K, Schopfer FJ, et al. STING palmitoylation as a therapeutic target[J]. Cell Mol Immunol, 2019, 16(3): 236-241. doi: 10.1038/s41423-019-0205-5
[24]	Miner JJ, Fitzgerald KA. A path towards personalized medicine for autoinflammatory and related diseases[J]. Nat Rev Rheumatol, 2023, 19(3): 182-189. doi: 10.1038/s41584-022-00904-2
[25]	Gray EE, Treuting PM, Woodward JJ, et al. Cutting edge: cGAS is required for lethal autoimmune disease in the Trex1-deficient mouse model of aicardi-goutières syndrome[J]. J Immunol, 2015, 195(5): 1939-1943. doi: 10.4049/jimmunol.1500969
[26]	Rodero MP, Tesser A, Bartok E, et al. Type Ⅰ interferon-mediated autoinflammation due to DNase Ⅱ deficiency[J]. Nat Commun, 2017, 8(1): 2176. doi: 10.1038/s41467-017-01932-3
[27]	Tansakul M, Thim-Uam A, Saethang T, et al. Deficiency of STING promotes collagen-specific antibody production and B cell survival in collagen-induced arthritis[J]. Front Immunol, 2020, 11: 1101. doi: 10.3389/fimmu.2020.01101
[28]	Mukai K, Ogawa E, Uematsu R, et al. Homeostatic regulation of STING by retrograde membrane traffic to the ER[J]. Nat Commun, 2021, 12(1): 61. doi: 10.1038/s41467-020-20234-9
[29]	Kato Y, Park J, Takamatsu H, et al. Apoptosis-derived membrane vesicles drive the cGAS-STING pathway and enhance type Ⅰ IFN production in systemic lupus erythematosus[J]. Ann Rheum Dis, 2018, 77(10): 1507-1515. doi: 10.1136/annrheumdis-2018-212988
[30]	Cheng FR, Su T, Liu Y, et al. Targeting lymph nodes for systemic immunosuppression using cell-free-DNA-scavenging and cGAS-inhibiting nanomedicine-In-hydrogel for rheumatoid arthritis immunotherapy[J]. Adv Sci, 2023, 10(26): e2302575. doi: 10.1002/advs.202302575
[31]	Glück S, Guey B, Gulen MF, et al. Innate immune sensing of cytosolic chromatin fragments through cGAS promotes senescence[J]. Nat Cell Biol, 2017, 19(9): 1061-1070. doi: 10.1038/ncb3586
[32]	Gulen MF, Samson N, Keller A, et al. cGAS-STING drives ageing-related inflammation and neurodegeneration[J]. Nature, 2023, 620(7973): 374-380. doi: 10.1038/s41586-023-06373-1
[33]	Yu QJ, Katlinskaya YV, Carbone CJ, et al. DNA-damage-induced type Ⅰ interferon promotes senescence and inhibits stem cell function[J]. Cell Rep, 2015, 11(5): 785-797. doi: 10.1016/j.celrep.2015.03.069
[34]	Taylor JM, Moore Z, Minter MR, et al. Type- Ⅰ interferon pathway in neuroinflammation and neurodegeneration: focus on Alzheimer’s disease[J]. J Neural Transm, 2018, 125(5): 797-807. doi: 10.1007/s00702-017-1745-4
[35]	Jauhari A, Baranov SV, Suofu Y, et al. Melatonin inhibits cytosolic mitochondrial DNA-induced neuroinflammatory signaling in accelerated aging and neurodegeneration[J]. J Clin Invest, 2021, 131(9): e150328. doi: 10.1172/JCI150328
[36]	Hinkle JT, Patel J, Panicker N, et al. STING mediates neurodegeneration and neuroinflammation in nigrostriatal α-synucleinopathy[J]. Proc Natl Acad Sci U S A, 2022, 119(15): e2118819119. doi: 10.1073/pnas.2118819119
[37]	Zaki-Dizaji M, Akrami SM, Azizi G, et al. Inflammation, a significant player of Ataxia-Telangiectasia pathogenesis[J]? Inflamm Res, 2018, 67(7): 559-570. doi: 10.1007/s00011-018-1142-y
[38]	Ergun SL, Fernandez D, Weiss TM, et al. STING polymer structure reveals mechanisms for activation, hyperactivation, and inhibition[J]. Cell, 2019, 178(2): 290-301. e10.
[39]	Zhou C, Chen X, Planells-Cases R, et al. Transfer of cGAMP into bystander cells via LRRC8 volume-regulated anion channels augments STING-mediated interferon responses and anti-viral immunity[J]. Immunity, 2020, 52(5): 767-781. e6.
[40]	Zhao KX, Huang JJ, Zhao Y, et al. Targeting STING in cancer: challenges and emerging opportunities[J]. Biochim Biophys Acta Rev Cancer, 2023, 1878(6): 188983. doi: 10.1016/j.bbcan.2023.188983
[41]	Chin EN, Yu CG, Vartabedian VF, et al. Antitumor activity of a systemic STING-activating non-nucleotide cGAMP mimetic[J]. Science, 2020, 369(6506): 993-999. doi: 10.1126/science.abb4255
[42]	Pan BS, Perera SA, Piesvaux JA, et al. An orally available non-nucleotide STING agonist with antitumor activity[J]. Science, 2020, 369(6506): eaba6098. doi: 10.1126/science.aba6098
[43]	Hall J, Brault A, Vincent F, et al. Discovery of PF-06928215 as a high affinity inhibitor of cGAS enabled by a novel fluorescence polarization assay[J]. PLoS One, 2017, 12(9): e0184843. doi: 10.1371/journal.pone.0184843
[44]	Padilla-Salinas R, Sun LJ, Anderson R, et al. Discovery of small-molecule cyclic GMP-AMP synthase inhibitors[J]. J Org Chem, 2020, 85(3): 1579-1600. doi: 10.1021/acs.joc.9b02666
[45]	Vincent J, Adura C, Gao P, et al. Small molecule inhibition of cGAS reduces interferon expression in primary macrophages from autoimmune mice[J]. Nat Commun, 2017, 8(1): 750. doi: 10.1038/s41467-017-00833-9
[46]	Lama L, Adura C, Xie W, et al. Development of human cGAS-specific small-molecule inhibitors for repression of dsDNA-triggered interferon expression[J]. Nat Commun, 2019, 10(1): 2261. doi: 10.1038/s41467-019-08620-4
[47]	Chu L, Li CH, Li YX, et al. Perillaldehyde inhibition of cGAS reduces dsDNA-induced interferon response[J]. Front Immunol, 2021, 12: 655637. doi: 10.3389/fimmu.2021.655637
[48]	An J, Woodward JJ, Sasaki T, et al. Cutting edge: Antimalarial drugs inhibit IFN-β production through blockade of cyclic GMP-AMP synthase-DNA interaction[J]. J Immunol, 2015, 194(9): 4089-4093. doi: 10.4049/jimmunol.1402793
[49]	Wang MD, Sooreshjani MA, Mikek C, et al. Suramin potently inhibits cGAMP synthase, cGAS, in THP1 cells to modulate IFN-β levels[J]. Future Med Chem, 2018, 10(11): 1301-1317. doi: 10.4155/fmc-2017-0322
[50]	Mukai K, Konno H, Akiba T, et al. Activation of STING requires palmitoylation at the Golgi[J]. Nat Commun, 2016, 7: 11932. doi: 10.1038/ncomms11932
[51]	Haag SM, Gulen MF, Reymond L, et al. Targeting STING with covalent small-molecule inhibitors[J]. Nature, 2018, 559(7713): 269-273. doi: 10.1038/s41586-018-0287-8
[52]	Hansen AL, Buchan GJ, Rühl M, et al. Nitro-fatty acids are formed in response to virus infection and are potent inhibitors of STING palmitoylation and signaling[J]. Proc Natl Acad Sci U S A, 2018, 115(33): E7768-E7775.
[53]	Su CF, Cheng T, Huang J, et al. 4-Octyl itaconate restricts STING activation by blocking its palmitoylation[J]. Cell Rep, 2023, 42(9): 113040. doi: 10.1016/j.celrep.2023.113040
[54]	Humphries F, Shmuel-Galia L, Jiang ZZ, et al. Targeting STING oligomerization with small-molecule inhibitors[J]. Proc Natl Acad Sci U S A, 2023, 120(33): e2305420120. doi: 10.1073/pnas.2305420120
[55]	Barasa L, Chaudhuri S, Zhou JY, et al. Development of LB244, an irreversible STING antagonist[J]. J Am Chem Soc, 2023, 145(37): 20273-20288. doi: 10.1021/jacs.3c03637
[56]	Li SL, Hong Z, Wang Z, et al. The cyclopeptide astin C specifically inhibits the innate immune CDN sensor STING[J]. Cell Rep, 2018, 25(12): 3405-3421. e7.
[57]	Siu T, Altman MD, Baltus GA, et al. Discovery of a novel cGAMP competitive ligand of the inactive form of STING[J]. ACS Med Chem Lett, 2019, 10(1): 92-97. doi: 10.1021/acsmedchemlett.8b00466
[58]	Hong Z, Mei JH, Li CH, et al. STING inhibitors target the cyclic dinucleotide binding pocket[J]. Proc Natl Acad Sci U S A, 2021, 118(24): e2105465118. doi: 10.1073/pnas.2105465118
[59]	Feng MX, Kong DP, Guo H, et al. Gelsevirine improves age-related and surgically induced osteoarthritis in mice by reducing STING availability and local inflammation[J]. Biochem Pharmacol, 2022, 198: 114975. doi: 10.1016/j.bcp.2022.114975

[1]	ZHANG Zhixing, DENG Hua, TANG Yun. Applications and challenges of artificial intelligence in the development of anticancer peptides[J]. Journal of China Pharmaceutical University, 2024, 55(3): 347-356. DOI: 10.11665/j.issn.1000-5048.2024040201
[2]	HU Zi’ang, GAO Liming, YU Wenying. Advances in the application of artificial intelligence in nucleic acid drug development[J]. Journal of China Pharmaceutical University, 2024, 55(3): 335-346. DOI: 10.11665/j.issn.1000-5048.2024033101
[3]	ZENG Hao, WU Guozhen, ZOU Wuxin, WANG Zhe, SONG Jianfei, SHI Hui, WANG Xiaojian, HOU Tingjun, DENG Yafeng. Optimization of Menin inhibitors based on artificial intelligence-driven molecular factory technology[J]. Journal of China Pharmaceutical University, 2024, 55(3): 326-334. DOI: 10.11665/j.issn.1000-5048.2024040904
[4]	TANG qian, CHEN Roufen, SHEN Zheyuan, CHI Xinglong, CHE Jinxin, DONG Xiaowu. Research progress of artificial intelligence-based small molecule generation models in drug discovery[J]. Journal of China Pharmaceutical University, 2024, 55(3): 295-305. DOI: 10.11665/j.issn.1000-5048.2024031501
[5]	XUE Feng, FENG Shuo, LI Jing. Application and prospect of artificial intelligence in antimicrobial peptides screening[J]. Journal of China Pharmaceutical University, 2023, 54(3): 314-322. DOI: 10.11665/j.issn.1000-5048.2023030901
[6]	GU Zhihao, GUO Wenhao, YAO Hequan, LI Xuanyi, LIN Kejiang. Research progress of the screening and generation of lead compounds based on artificial intelligence model[J]. Journal of China Pharmaceutical University, 2023, 54(3): 294-304. DOI: 10.11665/j.issn.1000-5048.2023042201
[7]	YU Zehao, ZHANG Leiming, ZHANG Mengna, DAI Zhiqi, PENG Chengbin, ZHENG Siming. Artificial intelligence-based drug development: current progress and future challenges[J]. Journal of China Pharmaceutical University, 2023, 54(3): 282-293. DOI: 10.11665/j.issn.1000-5048.2023041003
[8]	WANG Chao, XIAO Fu, LI Miaozhu, PAN Ying, DING Xiao, REN Feng, ZHAVORONKOV Alex, WANG Yazhou. Application progress of artificial intelligence in the screening and identification of drug targets[J]. Journal of China Pharmaceutical University, 2023, 54(3): 269-281. DOI: 10.11665/j.issn.1000-5048.2023041102
[9]	YAN Fangrong. Application and advance of artificial intelligence in biomedical field[J]. Journal of China Pharmaceutical University, 2023, 54(3): 263-268. DOI: 10.11665/j.issn.1000-5048.2023030304
[10]	Zhang Zunjian, Yu Shuqin, Xiang Bingren, An Dengkui. A New Artificial Neural Network Model:Combined Counter-Back Propagation and its Application[J]. Journal of China Pharmaceutical University, 1996, (11).

Cited By

Cited by

Periodical cited type(1)

赵倩，魏宇，郭凯敏，王文佳，周水平，孙鹤，方坚松，胡蕴慧. 人工智能结合生物网络对“养血清脑制剂”和“逍遥丸”组方的优化及验证. 中药药理与临床. 2024(04): 27-33 .

Other cited types(3)

Get Citation

PDF

XML

Article views PDF downloads Cited by(4)

Turn off MathJax

Article Contents

Abstract

References

Research progress of cGAS-STING signaling pathway modulators in immunotherapy